Shacham Sharon 4

What Happened Shacham Sharon, a director of Acrivon Therapeutics, received a derivative award on 2026-06-17 covering 20,275 shares. The filing reports an acquisition amount of 20,275 shares at $0.00 (derivative instrument). This was an award/grant (not an open‑market purchase or sale).

Key Details

• Transaction date: 2026-06-17; Form 4 filed: 2026-06-22 (appears later than the typical 2-business-day Form 4 deadline).
• Reported terms: 20,275 shares; acquisition price reported as $0.00; classified as a derivative (option award per footnote).
• Vesting: Footnote states the shares subject to the option vest on the date immediately preceding the issuer's next annual meeting of stockholders, subject to the reporting person’s continuous service through the vesting date.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No sale or immediate disposition reported.

Context This filing reflects an equity award (an option covering shares) rather than a cash purchase or sale. The award carries a vesting condition tied to continued service and the next annual meeting; such grants are common for directors as compensation or retention. The filing date suggests it was submitted several days after the transaction date, which may be later than the usual Form 4 reporting window.